Neuren Pharmaceuticals Limited is a biopharmaceutical company specializing in the development of novel therapies for neurodevelopmental disorders that typically emerge in early childhood. Headquartered in Australia and established in 2001, the company focuses on addressing highly debilitating conditions for which there are limited or no approved treatment options. Neuren’s lead therapy, DAYBUE (trofinetide), is designed for the treatment of Rett syndrome in both adult and pediatric populations, with development programs extending to Fragile X syndrome, Phelan-McDermid syndrome, Angelman syndrome, Pitt Hopkins syndrome, and Prader-Willi syndrome. All of these programs have received “orphan drug” designation in the United States—a regulatory incentive supporting treatments for rare diseases. Neuren also collaborates with global partners, such as providing exclusive worldwide licenses for certain indications. The company’s work holds particular significance within the healthcare and biotechnology sectors, as it seeks to serve urgent unmet medical needs in rare neurological diseases, thus playing a vital role in the landscape of innovation for pediatric and neurodevelopmental therapeutics.